NCT06705062View on ClinicalTrials.gov

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination with Post-engraftment Anti-thymoglobin As Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

July 1, 2028

Conditions
Allogeneic Hematopoietic Cell TransplantGraft Versus Host Disease
Interventions
DRUG

reduced-dose PTCy

Patients receiving reduced dose of PTCy at 35mg.kg on day +3 and +4 together with tacrolimus starting from day+5 and single dose of anti-thymoglobin (ATG) 2.5mg/kg at 72 hours after documentation of neutrophil engraftment.

DRUG

Standard dose PTCY

Patients receiving standard dose PTCy at 50mg/kg on day +3 and +4 with tacrolimus starting from day +5 and single dose of anti-thymoglobin at 2.5mg/kg 72 hours after documentation of neutrophil engraftment.

Trial Locations (1)

200025

Ruijin hsopital, Shanghai

All Listed Sponsors
collaborator

Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine

UNKNOWN

lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT06705062 - Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination with Post-engraftment Anti-thymoglobin As Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation | Biotech Hunter | Biotech Hunter